Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(RS)-MCPG
说明： Non-selective mGlu antagonist
化学名： (RS)-α-Methyl-4-carboxyphenylglycine
纯度： ≥99% (HPLC)
生物活性 for (RS)-MCPG
(RS)-MCPG is a non-selective group I/group II metabotropic glutamate receptor antagonist.
S-enantiomer and Sodium Salt also available.
技术数据 for (RS)-MCPG
| 分子量 | 209.2 |
| 公式 | C10H11NO4 |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 146669-29-6 |
| PubChem ID | 1222 |
| InChI Key | DNCAZYRLRMTVSF-UHFFFAOYSA-N |
| Smiles | NC(C(O)=O)(C)C1=CC=C(C(O)=O)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for (RS)-MCPG
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| 1.1eq. NaOH | 100 |
制备储备液 for (RS)-MCPG
以下数据基于产品分子量 209.2。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.78 mL | 23.9 mL | 47.8 mL |
| 5 mM | 0.96 mL | 4.78 mL | 9.56 mL |
| 10 mM | 0.48 mL | 2.39 mL | 4.78 mL |
| 50 mM | 0.1 mL | 0.48 mL | 0.96 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for (RS)-MCPG
参考文献 for (RS)-MCPG
参考文献是支持产品生物活性的出版物。
Collingridge and Watkins (1994) Phenylglycine derivatives as metabotropic glutamate receptor antagonists. TiPS 15 333 PMID: 7992387
Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-α-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195 PMID: 8381746
Joly et al (1995) Molecular, functional and pharmacological characterization of the metabotropic glutamate receptor Type 5 splice variants: comparison with mGluR1. J.Neurosci. 15 3970 PMID: 7751958
If you know of a relevant reference for (RS)-MCPG, please let us know.
关键词: (RS)-MCPG, (RS)-MCPG supplier, Non-Selective, mGlur, antagonists, Group, I, II, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, Non-selective, mGlu, 0336, Tocris Bioscience
12 篇 (RS)-MCPG 的引用文献
引用文献是使用了 Tocris 产品的出版物。 (RS)-MCPG 的部分引用包括：
Tronson et al (2010) Metabotropic glutamate receptor 5/Homer interactions underlie stress effects on fear. J Neurosci 68 1007 PMID: 21075228
Tang et al (2015) Stimulation-evoked Ca2+ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. J Neurosci 35 3016 PMID: 25698739
Petzold et al (2008) Coupling of neural activity to blood flow in olfactory glomeruli is mediated by astrocytic pathways. Biol Psychiatry 58 897 PMID: 18579080
Shankar et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 837 PMID: 18568035
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Oh et al (2013) Synapse-specific and size-dependent mechanisms of spine structural plasticity accompanying synaptic weakening. Proc Natl Acad Sci U S A 110 E305 PMID: 23269840
Zhang and Lisman (2012) Activity-dependent regulation of synaptic strength by PSD-95 in CA1 neurons. Cereb Cortex 107 1058 PMID: 22114157
Zhuo et al (1999) On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus. Learn Mem 5 467 PMID: 10489262
Ohba et al (2005) BDNF locally potentiates GABAergic presynaptic machineries: target-selective circuit inhibition. Proc Natl Acad Sci U S A 15 291 PMID: 15238431
Muddashetty et al (2007) Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 27 5338 PMID: 17507556
Jan and Westbrook (2007) Disynaptic amplification of metabotropic glutamate receptor 1 responses in the olfactory bulb. J Neurosci 27 132 PMID: 17202480
Takayasu et al (2006) Glial glutamate transporters maintain one-to-one relationship at the climbing fiber-Purkinje cell synapse by preventing glutamate spillover. J Neurophysiol 26 6563 PMID: 16775144
您是否知道使用了 Tocris (RS)-MCPG 的优秀论文？ 请告知我们.
(RS)-MCPG 的评论
平均评分: 4 (Based on 1 Review.)
Have you used (RS)-MCPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Suppression of mGluRs activated by glutamate application.
By
Sergiy Sylantyev on 10/15/2020
种属： Human
细胞系/组织： Stem cell - derived neurons
(RS)-MCPG was in use to prevent contamination of NMDA-receptor – generated response to prolonged application of glutamate with (possible) impact from metabotropic glutamate receptors (mGluRs). APV, applied after glutamate and glycine, fully suppressed NMDA-receptor response, thus suggesting no input from mGluRs (see illustration). MCPG works as expected, but takes quite a long time to dissolve for stock preparation.
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.